Women were left out of medical research until 1993. Here is what that still means for you.
Until 1993, women of childbearing age were excluded from most early-stage clinical trials in the United States under a 1977 FDA guideline. Drugs were tested mainly on men and then prescribed to everyone. The NIH Revitalization Act of 1993 reversed that, but decades of dosing guidance had already been written from male data, and some of it has still not been revisited.
If you have ever been told your labs are normal while you feel anything but, it is worth knowing how the reference ranges were built.
The 1977 rule
In 1977 the FDA issued guidance that effectively excluded women of childbearing potential from most early-phase clinical trials. The reasoning was protective. The thalidomide harms were recent, and the concern was fetal exposure during studies.
The effect was that for roughly sixteen years, the people in the rooms where dosing was worked out were overwhelmingly men. Drugs were then approved and prescribed to a population half of whom had barely been studied.
What changed in 1993
The NIH Revitalization Act of 1993 required investigators applying for NIH funding to include women and minorities in clinical research, or to justify in writing why they had not. It reversed the 1977 guidance directly.
That is the pivot point. It is also, worth saying plainly, within the lifetime of most people reading this.
Why 1993 did not fix it
Two things carried forward.
The back catalogue was never re-run. A drug approved in 1985 did not get re-studied because the rules changed in 1993. Its label carried on.
Inclusion is not the same as analysis. A trial can enrol women and still report a single pooled result, which tells you nothing about whether the drug behaves differently in a female body.
The clearest example
Zolpidem, sold as Ambien, was approved in 1992 and taken by millions of people for two decades.
In January 2013, the FDA instructed manufacturers to cut the recommended dose for women. Immediate-release products went from 10 mg to 5 mg. Extended release went from 12.5 mg to 6.25 mg. The reason was that women clear the drug more slowly, which made next-morning impairment more likely, including behind the wheel.
Nothing about female physiology changed in 2013. The data did. For twenty years, a very large number of women were taking double what they should have been, and the reason nobody caught it earlier is the reason described above.
What to do with this
This is not an argument that medicine is useless or that your doctor is against you. It is an argument for asking two specific questions, which are reasonable and which most clinicians will answer happily:
- Was this dose studied in women, and was the result reported separately?
- What is the reference range for this test, and was it built from a population like me?
The second one matters more than people expect. Reference ranges are statistical, not biological. They describe where most of a sampled group fell. If the sampled group did not look like you, "normal" is a weaker statement than it sounds.
The practical part
None of the above changes what actually moves the needle, and all of it is free.
Sleep first. Short sleep raises appetite signalling and lowers the proportion of weight lost that comes from fat. If one thing changes this month, make it this one.
Protein earlier in the day. Most people under-eat it at breakfast and then cannot catch up. Aim to front-load rather than increase the total.
Load the tissue. Resistance work two or three times a week protects muscle during any deficit. It is the difference between losing weight and losing yourself.
Walk. Unglamorous, and the most reliably underrated variable in every dataset on this.
FAQ
When were women first required to be included in US clinical trials?
The NIH Revitalization Act of 1993 required investigators applying for NIH funding to include women and minority participants, or to justify their exclusion in writing.
Why were women excluded from clinical trials before 1993?
A 1977 FDA guideline excluded women of childbearing potential from most early-phase trials, out of concern about fetal exposure following the thalidomide harms.
Are drug doses different for women?
For some drugs, yes. In 2013 the FDA lowered the recommended zolpidem dose for women specifically, from 10 mg to 5 mg for immediate-release forms, because women clear the drug more slowly.
Does including women in a trial mean the results are analysed by sex?
No. A study can enrol women and still publish a single pooled result. Sex differences only surface if the analysis is done and reported separately.
Should I change my medication based on this article?
No. This is background, not advice. Bring the two questions above to the person who prescribes for you.
Sources
- NIH Revitalization Act of 1993, Public Law 103-43, inclusion requirements for women and minorities in clinical research.
- FDA, 1977 General Considerations for the Clinical Evaluation of Drugs, the guideline excluding women of childbearing potential from early-phase trials.
- FDA Drug Safety Communication, January 2013, recommending lower zolpidem doses for women.
Get the next one
Get new pieces as they go up. No more than one email a month, and nothing sold to you.
Unsubscribe in one click. We never sell or share the list.